Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) insider Sean Maduck sold 3,664 shares of the firm's stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $114.49, for a total transaction of $419,491.36. Following the transaction, the insider directly owned 9,755 shares in the company, valued at $1,116,849.95. The trade was a 27.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Sean Maduck also recently made the following trade(s):
- On Monday, August 10th, Sean Maduck sold 1,031 shares of Corcept Therapeutics stock. The stock was sold at an average price of $114.52, for a total transaction of $118,070.12.
- On Monday, August 3rd, Sean Maduck sold 20,305 shares of Corcept Therapeutics stock. The stock was sold at an average price of $114.70, for a total transaction of $2,328,983.50.
- On Wednesday, July 1st, Sean Maduck sold 25,000 shares of Corcept Therapeutics stock. The shares were sold at an average price of $88.35, for a total transaction of $2,208,750.00.
- On Monday, June 1st, Sean Maduck sold 25,000 shares of Corcept Therapeutics stock. The stock was sold at an average price of $70.21, for a total transaction of $1,755,250.00.
- On Wednesday, May 27th, Sean Maduck sold 75,000 shares of Corcept Therapeutics stock. The stock was sold at an average price of $65.59, for a total value of $4,919,250.00.
Corcept Therapeutics Stock Up 0.8%
Shares of NASDAQ CORT opened at $118.10 on Wednesday. The company has a market capitalization of $12.77 billion, a PE ratio of 281.20 and a beta of 0.45. The stock's 50 day moving average price is $95.03 and its 200-day moving average price is $63.09. Corcept Therapeutics Incorporated has a twelve month low of $28.66 and a twelve month high of $122.21.
Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last issued its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $0.36 EPS for the quarter, topping analysts' consensus estimates of $0.02 by $0.34. Corcept Therapeutics had a return on equity of 8.26% and a net margin of 6.52%.The business had revenue of $256.15 million for the quarter, compared to analyst estimates of $221.15 million. During the same period last year, the company posted $0.29 earnings per share. Corcept Therapeutics's quarterly revenue was up 31.7% compared to the same quarter last year. As a group, research analysts expect that Corcept Therapeutics Incorporated will post 1.13 EPS for the current fiscal year.
Analyst Ratings Changes
A number of brokerages recently weighed in on CORT. Canaccord Genuity Group boosted their price target on shares of Corcept Therapeutics from $135.00 to $150.00 and gave the stock a "buy" rating in a report on Wednesday, July 29th. Wolfe Research downgraded shares of Corcept Therapeutics from a "peer perform" rating to an "underperform" rating and set a $50.00 price objective for the company. in a report on Monday, July 27th. Piper Sandler reaffirmed an "overweight" rating and issued a $165.00 price objective (up from $88.00) on shares of Corcept Therapeutics in a research report on Thursday, July 30th. Truist Financial started coverage on shares of Corcept Therapeutics in a research note on Tuesday. They issued a "buy" rating and a $164.00 target price on the stock. Finally, Wall Street Zen upgraded shares of Corcept Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 1st. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $138.17.
Read Our Latest Analysis on Corcept Therapeutics
Institutional Trading of Corcept Therapeutics
Hedge funds have recently made changes to their positions in the company. Royal Bank of Canada grew its stake in shares of Corcept Therapeutics by 18.9% during the 1st quarter. Royal Bank of Canada now owns 15,385 shares of the biotechnology company's stock worth $1,757,000 after acquiring an additional 2,444 shares during the period. Amundi bought a new stake in Corcept Therapeutics in the 1st quarter valued at about $450,000. NewEdge Advisors LLC purchased a new stake in Corcept Therapeutics during the first quarter valued at about $518,000. EverSource Wealth Advisors LLC boosted its position in Corcept Therapeutics by 273.3% during the second quarter. EverSource Wealth Advisors LLC now owns 1,441 shares of the biotechnology company's stock worth $106,000 after purchasing an additional 1,055 shares during the period. Finally, Marshall Wace LLP boosted its position in Corcept Therapeutics by 795.3% during the second quarter. Marshall Wace LLP now owns 46,200 shares of the biotechnology company's stock worth $3,391,000 after purchasing an additional 41,040 shares during the period. 93.61% of the stock is currently owned by institutional investors.
Corcept Therapeutics Company Profile
(
Get Free Report)
Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company's scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.
The company's flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing's syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
